Journal articles: 'Silodosin'

1

Ahmed, Masud, Prodyut Kumar Saha, Kartik Chandra Ghosh, SK Amirul Islam, and Nirupom Mondal. "Comparative study between Silodosin alone and Silodosin plus Tadalafil for the medical management of lower Ureteric Stone in South-Western part of the Bangladesh." Bangladesh Journal of Urology 23, no. 1 (November 15, 2020): 67–71. http://dx.doi.org/10.3329/bju.v23i1.50293.

Full text

Abstract:

Objective: To compare the treatment outcome of Silodosin alone and Silodosin plusTadalafil as a medical expulsive therapy (MET) of lower ureteric stone in south-westernpart of Bangladesh. Methodology: The study was conducted in a tertiary hospital in Khulna, over a periodof 12 months (January 2019 to December 2019). Out of 108 patients, 100 meet theinclusion criteria who were purposively assigned into 2 groups. 48 patients included inSilodosin alone group and 52 in Silodosin plus Tadalafil group. Result: There was a significant higher stone expulsion rate in Silodosin plus Tadalafilthan Silodosin alone which was 88.46% vs75% respectively (P value 0.02). The meanstone expulsion time of Silodosin alone was14.33 (±3.1) days and Silodosin plus Tadalafilwas 11.48(±2.3) days (P value 0.001). The episodes of pain in Silodosin alone were0.7(±0.06) and 0.6(±0.2) in Silodosin plus Tadalafil group that was statisticallysignificant. Conclusion: The present study concludes that Silodosin plus tadalafil combinationtherapy significantly increases ureteric stone expulsion rate and decreases the expulsiontime and pain episodes than treatment with silodosin alone. Bangladesh Journal of Urology, Vol. 23, No. 1, January 2020 p.67-71

APA, Harvard, Vancouver, ISO, and other styles

2

Curran, Monique P. "Silodosin." Drugs 71, no. 7 (May 2011): 897–907. http://dx.doi.org/10.2165/11204780-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tanaka, Yoshinori, Yasushi Tanuma, and Naoya Masumori. "The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia." Advances in Urology 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/4842025.

Full text

Abstract:

Objectives. The persistence of silodosin and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) were evaluated in real-life clinical practice.Methods. A total of 81 previously untreated Japanese patients diagnosed with LUTS/BPH were treated with silodosin monotherapy and prospectively followed for 4 years. The persistence rate was estimated using the Kaplan-Meier method. If silodosin had to be terminated or a patient did not come to the hospital, the reason was determined.Results. The 6-month, 1-year, 2-year, 3-year, and 4-year persistence rates were 63.0%, 56.8%, 50.6%, 44.4%, and 35.8%, respectively. The most frequent reason (22.2%) for withdrawal was symptom resolution. After silodosin treatment, the international prostate symptom score and the quality of life index were significantly improved and maintained for 4 years.Conclusions. 35.8% of previously untreated Japanese patients continued silodosin for 4 years. Many patients terminated silodosin for various reasons, the most frequent of which was symptom resolution. The effects of silodosin were maintained when the patients continued treatment.Trial Registration. This study was approved by the institutional review board of Hokkaido Prefectural Esashi Hospital (number 2007-2) and was registered in a public trial registry (UMIN000026910).

APA, Harvard, Vancouver, ISO, and other styles

4

Jung, Hae Do, Kang Su Cho, Dae Young Jun, Jae Yong Jeong, Young Joon Moon, Doo Yong Chung, Dong Hyuk Kang, Seok Cho, and Joo Yong Lee. "Silodosin versus Tamsulosin for Medical Expulsive Therapy of Ureteral Stones: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials." Medicina 58, no. 12 (December 6, 2022): 1794. http://dx.doi.org/10.3390/medicina58121794.

Full text

Abstract:

Background and Objectives: This systematic review and meta-analysis of randomized controlled trials was performed to compare the therapeutic effects and safety profiles of silodosin and tamsulosin for medical expulsive therapy (MET) of ureteral stones. Materials and Methods: We searched PubMed, EMBASE, the Cochrane Library, and Web of Science to identify articles published before July 2022 that described randomized controlled trials comparing silodosin and tamsulosin for MET of ureteral stones. Endpoints were stone expulsion rate, stone expulsion time, and total complication rate. Results: In total, 14 studies were included in our analysis. The size of ureteral stones was <1 cm. Compared with tamsulosin, silodosin resulted in a significantly higher stone expulsion rate (p < 0.01, odds ratio (OR) = 2.42, 95% confidence interval (CI) = 1.91 to 3.06, I2 = 0%) and significantly shorter stone expulsion time (p < 0.01, mean difference = −3.04, 95% CI = −4.46 to −1.63, I2 = 89%). The total complication rate did not significantly differ between silodosin and tamsulosin (p = 0.33, OR = 1.15, 95% CI = 0.87 to 1.52, I2 = 7%). Conclusions: Compared with tamsulosin, silodosin resulted in significantly better expulsion of ureteral stones <1 cm. The total complication rate did not significantly differ between silodosin and tamsulosin. Thus, silodosin may be superior to tamsulosin for MET of ureter stones <1 cm.

APA, Harvard, Vancouver, ISO, and other styles

5

Imperatore, Vittorio, Ferdinando Fusco, Massimiliano Creta, Sergio Di Meo, Roberto Buonopane, Nicola Longo, Ciro Imbimbo, and Vincenzo Mirone. "Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin." Archivio Italiano di Urologia e Andrologia 86, no. 2 (June 30, 2014): 103. http://dx.doi.org/10.4081/aiua.2014.2.103.

Full text

Abstract:

Objectives: To compare the efficacy and safety of tamsulosin and silodosin in the context of medical expulsive therapy (MET) of distal ureteric stones. Patients and methods: Observational data were collected retrospectively from patients who received silodosin (N = 50) or tamsulosin (N = 50) as MET from January 2012 to January 2013. Inclusion criteria were: patients aged ≥ 18 years with a single, unilateral, symptomatic, radiopaque ureteric stone of 10 mm or smaller in the largest dimension located between the lower border of the sacroiliac joint and the vesico-ureteric junction. Stone expulsion rate, stone expulsion time, number of pain episodes, need for analgesics use, incidence of side effects were compared. Results: Stone-expulsion rate in the silodosin and in the tamsulosin groups were 88% and 82%, respectively (p not significant). Mean expulsion times were 6.7 and 6.5 days in the silodosin and tamsulosin group, respectively (p not significant). Mean number of pain episodes were 1.6 and 1.7 in the silodosin and tamsulosin group, respectively (p not significant). The mean number of analgesic requirement was 0.84 and 0.9 for the silodosin and tamsulosin group, respectively (p not significant). Overall, incidence of side effects was similar in both groups. Patients taking silodosin experienced an higher incidence of retrograde ejaculation but a lower incidence of side effects related to peripheral vasodilation when compared to patients taking tamsulosin. Subgroup analysis demonstrated significantly lower mean expulsion times and pain episodes in patients with stones ≤ 5 mm in both groups. Conclusions: Tamsulosin and silodosin are equally effective as MET for distal ureteric stones sized 10 mm or smaller. MET with silodosin is associatd with a lower incidence of side effects related to peripheral vasodilation but an higher incidence of retrograde ejaculation when compared to tamsulosin.

APA, Harvard, Vancouver, ISO, and other styles

6

Cakiroglu, Basri, Aydin Ismet Hazar, Orhun Sinanoglu, Ersan Arda, and Sinan Ekici. "Comparison of transurethral incision of the prostate and silodosin in patients having benign prostatic obstruction in terms of retrograde ejaculation." Archivio Italiano di Urologia e Andrologia 89, no. 1 (March 31, 2017): 31. http://dx.doi.org/10.4081/aiua.2017.1.31.

Full text

Abstract:

Background: To compare the functional outcomes and retrograde ejaculation (RE) after transurethral incision of the prostate (TUIP) or silodosin in bladder outlet obstruction (BOO) secondary to a small prostate. Methods: Prospectively collected data from December 2011 through December 2014 of 192 LUTS patients having fertility concerns with prostate volume smaller than 40 ml receiving either TUIP or silodosin treatment were prospectively reviewed. The treatment outcomes were evaluated and compared. Results: TUIP was performed in 96 cases and silodosin 8 mg was prescribed in 96 cases. At 12th months after TUIP or continuous silodosin treatment, the decrease in mean International Prostate Symptom Score (IPSS) and postvoiding residual urine (PVR) and the improvement of mean maximal flow rate (Qmax) were significant (p = 0.000). The improvement in IPPS and Qmax was significantly higher in TUIP group compared to silodosin group (p = 0.005, p = 0.000) with a lower rate of retrograde ejaculation (RE) in TUIP group. (11/96 vs 33/96) (p = 0.000) Conclusions: Both TUIP and silodosin ensures comparable improvement in PVR, IPSS and Qmax with a lower rate of RE on the TUIP group in prostates weighing less than 40 grams suggesting that TUIP is a better choice in younger patiens seeking preservation of ejaculation with fertility concerns.

APA, Harvard, Vancouver, ISO, and other styles

7

Klimi, Eleni. "A Probable Case of Mucosal Fixed Drug Eruption Following Treatment with Silodosin." Sultan Qaboos University Medical Journal [SQUMJ] 18, no. 3 (December 19, 2018): 402. http://dx.doi.org/10.18295/squmj.2018.18.03.025.

Full text

Abstract:

A fixed drug eruption consists of erythematous patches that appear on the skin and/or mucous membranes following administration of a drug which, once healed, leaves residual hyperpigmentation. We report a 76-year-old male who presented to the Thriasio General Hospital, Athens, Greece, in 2016 with erythema, oedema and blistering of the lower lip and glans penis following the administration of silodosin for benign prostatic hyperplasia. The eruption regressed two weeks after silodosin was discontinued.Keywords: Drug Eruption; Mucous Membranes; Erythema; Blister; Silodosin; Case Report; Greece.

APA, Harvard, Vancouver, ISO, and other styles

8

Hagovska, Magdalena, and Jan Svihra. "Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)." International Journal of Environmental Research and Public Health 18, no. 21 (October 30, 2021): 11426. http://dx.doi.org/10.3390/ijerph182111426.

Full text

Abstract:

The aim of our study will be to evaluate the effect of combining pelvic floor muscle training (PFMT) with the urgency-suppression technique and silodosin in comparison with silodosin alone in men with Benign Prostatic Hyperplasia (BPH) and Overactive Bladder (OAB) after 12 weeks of treatment. The primary outcome will be a change in the number of voidings and intensity of urgencies over 24 h using a micturition diary, and the secondary outcomes will be a change in lower urinary tract symptoms, a change in incontinence quality of life, a change in patients’ global impression of improvement, and a lower incidence of adverse events. A randomized intervention parallel multicenter study will be conducted in collaboration with 45 urological clinics at the national level. Patients will be assigned at a 1:1 ratio to the experimental and control groups using simple randomization according to odd and even patient sequence numbers in each ambulatory clinic. The experimental group will receive oral silodosin at a daily dose of 8 mg once daily and pelvic floor muscle training (PFMT) 5 times a week for 20–30 min a day, for 12 weeks. The control group will receive oral treatment with silodosin at a daily dose of 8 mg once daily for 12 weeks. The study protocol presents the starting points and design of a randomized, interventional, parallel, multicenter study looking at the effect of a combination of silodosin and PFMT versus silodosin treatment in men with BPH and OAB.

APA, Harvard, Vancouver, ISO, and other styles

9

Oyama, Nobuyuki, Yoshitaka Aoki, Hideaki Ito, Yoshiji Miwa, Hironobu Akino, Yoshitaka Sato, Hiroki Shioura, Hirohiko Kimura, and Osamu Yokoyama. "Alpha 1-Adrenoceptor Blocker May Improve Not Only Voiding But Also Storage Lower Urinary Tract Symptoms Caused by 125I Brachytherapy for Prostate Cancer." ISRN Urology 2014 (March 30, 2014): 1–8. http://dx.doi.org/10.1155/2014/140654.

Full text

Abstract:

Purpose. To assess changes in lower urinary tract symptoms (LUTS) within 1 year after brachytherapy in patients receiving alpha 1-adrenoceptor antagonists. Methods. We retrospectively evaluated 116 patients who underwent 125I prostate brachytherapy in our institute. Seventy-one patients were treated with a combination of external beam radiation therapy and brachytherapy. Alpha 1-adrenoceptor antagonists were prescribed to all patients after brachytherapy. International Prostate Symptom Score (IPSS) forms and postvoid residual urine volume were recorded at all follow-up visits. Results. Forty-nine patients were given tamsulosin hydrochloride, 32 were given silodosin hydrochloride, and 35 were given naftopidil for up to 6 months after seed implantation. Patients given tamsulosin or naftopidil tended to show a higher peak IPSS and slower recovery to baseline values than those given silodosin. The patients given naftopidil showed an insufficient recovery in storage symptoms in naftopidil group in comparison with tamsulosin group at 3 months and with silodosin group at 6 and 9 months. Conclusions. In the management of LUT after brachytherapy, silodosin may provide a more favorable improvement. Silodosin and tamsulosin may have an advantage in improving not only voiding but also storage lower urinary tract symptoms after brachytherapy.

APA, Harvard, Vancouver, ISO, and other styles

10

YAMAZAKI, Yoshinobu. "Development of Silodosin." YAKUGAKU ZASSHI 126, Special (March 1, 2006): 207–8. http://dx.doi.org/10.1248/yakushi.kj00004483554.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

YAMAZAKI, Yoshinobu. "Development of Silodosin." YAKUGAKU ZASSHI 126, Special_Issue (2006): 207–8. http://dx.doi.org/10.1248/yakushi.126.207.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Montorsi, Francesco. "Profile of Silodosin." European Urology Supplements 9, no. 4 (July 2010): 491–95. http://dx.doi.org/10.1016/j.eursup.2010.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Shin, Hyun Jin, Woo Suk Choi, Shin-Hyo Lee, Andrew G. Lee, Aram Kim, Hyoung Keun Park, Sung Hyun Paick, and Hyeong Gon Kim. "Improvement in Near Vision Following Silodosin Treatment in Patients With Lower Urinary Tract Symptoms." International Neurourology Journal 25, no. 2 (June 30, 2021): 164–71. http://dx.doi.org/10.5213/inj.2040274.137.

Full text

Abstract:

Purpose: The objective of this study was to investigate the change in near visual function after the administration of oral silodosin to patients with lower urinary tract symptoms (LUTS).Methods: This prospective study included treatment-naive patients who were scheduled to start treatment with silodosin for LUTS. A comprehensive ophthalmological evaluation including the near vision and the automated pupillometry was performed at baseline and after 3 months of silodosin treatment. For subjective assessment of near visual ability and satisfaction, a Near Activity Visual Questionnaire-10 (NAVQ-10) was also used at the same time (higher scores indicating worse quality).Results: Of 23 patients enrolled in this study, 15 continued with silodosin (8 mg once daily) treatment for 3 months and completed a follow-up evaluation. The mean age of participants was 60.4±8.4 years. Distant visual acuity and spherical error were unchanged after silodosin treatment. However, near vision acuity (logMAR) was improved after treatment (right, 0.47±0.36 vs. 0.38±0.39, P=0.018; left, 0.41±0.37 vs. 0.31±0.34, P=0.068; both, 0.27±0.26 vs. 0.21±0.27, P=0.043). Pupil size under room light decreased significantly in both eyes (right, 3.77±0.60 vs. 3.16±0.58, P=0.001; left, 3.72±0.80 vs. 3.21±0.75, P=0.002). The Rasch scale at NAVQ-10 improved from 54.7±9.9 to 48.5±11.2 (P=0.004).Conclusions: This preliminary study demonstrated that highly selective alpha-1A adrenergic receptor antagonists such as silodosin improve near visual acuity and quality in patients with LUTS/benign prostatic hyperplasia. Decrease in pupil size caused by inhibition of adrenergic alpha 1 mediated contraction of iris dilator muscle is a possible mechanism underlying improved near vision.

APA, Harvard, Vancouver, ISO, and other styles

14

Cholaraju, Ranadheer S., Karthik Aithal, P. S. M. Ameer Ali, and Althaf Khan. "Effect of α-adrenergic blockers silodosin in the management of distal ureteric calculus." International Surgery Journal 7, no. 3 (February 26, 2020): 689. http://dx.doi.org/10.18203/2349-2902.isj20200521.

Full text

Abstract:

Background: Urinary calculus disease is one of the 3 most common urological diseases. It affects about 12% of the world population and has become a worldwide health problem. Of all the urinary tract stones 20% are ureteral stones, of which 70% are found in the distal ureter. The objective of the study is to study the effect of silodosin in the passage of calculi in the distal ureter compared to non-steroidal anti-inflammatory drugs (NSAIDs) (diclofenac sodium) and oral fluids.Methods: This study included a total of 90 patients between the study period from October 2016 to October 2018. 45 patients were chosen randomly and advised to take plenty of oral fluids and treated with NSAIDs and the other 45 patients were treated with silodosin 8 mg HS for one month along with oral fluids and NSAIDs. After 1 month if the stone was passed successfully, it was confirmed with ultrasonography, if failed, advised for surgery.Results: Majority of the patients were in the age group of 20-45 yrs. The mean size of the calculus was 5.60 cm on the right side and 5.71 cm on the left side. Out of the 45 patients who were on treatment with silodosin 35 patients had passed the calculi and 10 patients had no results with a success rate of 77.7%. In the 45 patients who were not on silodosin, 8 patients passed the calculi and 37 patients did not pass the calculi. 21 patients among the 45 underwent urethrorenoscopy.Conclusions: Silodosin is an effective and safe drug in the management of calculi in the distal ureter.

APA, Harvard, Vancouver, ISO, and other styles

15

Matsukawa, Yoshihisa, Shun Takai, Tsuyoshi Majima, Yasuhito Funahashi, Masashi Kato, Tokunori Yamamoto, and Momokazu Gotoh. "Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics." Therapeutic Advances in Urology 10, no. 9 (June 26, 2018): 263–72. http://dx.doi.org/10.1177/1756287218783646.

Full text

Abstract:

Background: The aim of this research was to investigate intermediate-term effects of silodosin on lower urinary tract functions and symptoms in patients with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) according to prostate size, using urodynamics. Methods: A total of 70 untreated outpatients with a prostate volume <40 ml [small prostate (SP) group] and 70 with prostate volume ⩾40 ml [large prostate (LP) group] were prospectively enrolled and treated by monotherapy with silodosin for 24 months. Changes in parameters from baseline to 3 months and 24 months after silodosin administration were assessed based on LUTS, voiding and storage function. In addition, withdrawal rates of silodosin due to insufficient effects were compared between the two groups and factors to influence the withdrawal were investigated. Results: The International Prostate Symptom Score (IPSS), bladder outlet obstruction index (BOOI), and detrusor overactivity (DO) improved significantly for the 2-year follow up in both groups as compared with the baseline. IPSS, BOOI and DO improved by 40.4%, 41.3%, and 48.1% in the SP group, 32.7%, 35.9%, and 34.4% in the LP group at 3 months, while, 44.3%, 43.5%, and 63.0% in the SP group, 22.6%, 21.1%, and 34.4% in the LP group at 24 months, respectively. Improvement rates in the IPSS and BOOI at 3 months were maintained until 24 months in the SP group, but decreased in the LP group. Storage function improvements continued in both groups for 2 years. Dropout rate due to unsatisfactory effects was significantly higher in the LP group (20% versus 8.6%). Maximum flow rate, BOOI, and intravesical prostatic protrusion had a significant influence on the withdrawal of silodosin treatment in the LP group. Conclusions: Silodosin significantly improved lower urinary tract functions for 2 years in patients with LUTS/BPH, regardless of prostate size. However, LUTS and BOO improvements tended to decrease in patients with a large prostate (>40 ml) in the intermediate term.

APA, Harvard, Vancouver, ISO, and other styles

16

Liu, Hui, Fei Lv, and Yuan Liu. "Improved Preparation of Silodosin." Organic Preparations and Procedures International 51, no. 3 (May 4, 2019): 287–93. http://dx.doi.org/10.1080/00304948.2019.1600127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

González-Álvarez, Isabel, Bárbara Sánchez-Dengra, Raquel Rodriguez-Galvez, Alejandro Ruiz-Picazo, Marta González-Álvarez, Alfredo García-Arieta, and Marival Bermejo. "Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients." Pharmaceutics 14, no. 12 (November 23, 2022): 2565. http://dx.doi.org/10.3390/pharmaceutics14122565.

Full text

Abstract:

Some years ago, excipients were considered inert substances irrelevant in the absorption process. However, years of study have demonstrated that this belief is not always true. In this study, the reasons for a bioequivalence failure between two formulations of silodosin are investigated. Silodosin is a class III drug according to the Biopharmaceutics Classification System, which has been experimentally proven by means of solubility and permeability experiments. Dissolution tests have been performed to identify conditions concordant with the non-bioequivalent result obtained from the human bioequivalence study and it has been observed that paddles at 50 rpm are able to detect inconsistent differences between formulations at pH 4.5 and pH 6.8 (which baskets at 100 rpm are not able to do), whereas the GIS detects differences at the acidic pH of the stomach. It has also been observed that the differences in excipients between products did not affect the disintegration process, but disintegrants did alter the permeability of silodosin through the gastrointestinal barrier. Crospovidone and povidone, both derivatives of PVP, are used as disintegrants in the test product, instead of the pregelatinized corn starch used in the reference product. Permeability experiments show that PVP increases the absorption of silodosin—an increase that would explain the greater Cmax observed for the test product in the bioequivalence study.

APA, Harvard, Vancouver, ISO, and other styles

18

Zhou, Jun, Yunpeng Liu, Hailiang Zhu, He Zhu, and Peng George Wang. "Synthesis of silodosin glucuronide and its deuterated counterpart: solving a problematic O-glycosylation of a nitrogen-containing molecule." Heterocyclic Communications 23, no. 3 (June 27, 2017): 187–95. http://dx.doi.org/10.1515/hc-2017-0092.

Full text

Abstract:

AbstractWe report here the first chemical synthesis of silodosin glucuronide, a metabolite of the α1A-adrenoceptor antagonist silodosin, and its deuterium-labeled counterpart. As a key synthetic step, the incorporation of a glucuronosyl unit onto silodosin invariably led to either an undesired orthoester or a complex mixture under an array of standard glycosylation conditions. This problematic O-glycosylation may be attributed to the presence of multiple basic groups that could neutralize the acidic activators, decrease the nucleophilicity of a hydroxy group via hydrogen bond or even facilitate acyl migration side reactions. After elaborate tuning of reaction conditions, success was eventually achieved by using perbenzoylated d-glucuronosyl N-phenyltrifluroacetimidate (PTFA) as donor in combination with a procedure of sequential addition of TMSOTf. This protocol is potentially general for the glycosylation of other nitrogen-containing small molecule drugs.

APA, Harvard, Vancouver, ISO, and other styles

19

Sentürk, Aykut Buğra, Cemil Aydin, Musa Ekici, Muhammet Yaytokgil, Ali Akkoc, and Mehmet Murat Baykam. "Comparison of three most frequently used alpha blocker agents in medical expulsive therapy for distal ureteral calculi, result of a retrospective observational study." Archivio Italiano di Urologia e Andrologia 90, no. 1 (March 31, 2018): 25. http://dx.doi.org/10.4081/aiua.2018.1.25.

Full text

Abstract:

Purpose: In this study, we compared the effects of three agents frequently used in daily life for medical expulsive therapy. Materials and methods: A total of 143 patients meeting the criteria were included in the study. Patients were divided into three homogeneous drug groups which were tamsulosin group (n:48), alfuzosin group (n:47) and silodosin group (n:48). The time of stone expulsion, analgesic needs, side effects of the medicine and endoscopic intervention needs of the patients were recorded. Results: The rate of stone expulsion was 70.8% (n:34) in tamsulosin group, 70.2% (n:33) in alfuzosin group, and 75% (n:36) in silodosin group. No significant difference was observed among the rates of stone expulsion in three groups, and the rates of stone expulsion were similar (p = 0.778). The duration of stone expulsion was significantly different in the groups (p = 0.012): the time of stone expulsion for tamsulosin was 2.33 ± 0.78 days longer than for Silodosin, indicating a significant difference. There was no significant difference between tamsulosin-alfuzosin and silodosin-alfuzosin (respectively p = 0.147, p = 0.925). Conclusions: The results of this study showed that medical expulsive therapy by using alpha blocker agents is safe and efficacious. This option must be kept in mind for patients who do not ask for surgery as the first-step treatment for eligible patients.

APA, Harvard, Vancouver, ISO, and other styles

20

Sadasivam, Balakrishnan, Santenna Chenchula, and Avik Ray. "Systematic Review of Efficacy and Safety of Silodosin in Medical Expulsive Therapy for the Management of Ureteral Stones – Based on Indian Evidences." Biomedical and Pharmacology Journal 14, no. 02 (June 30, 2021): 733–38. http://dx.doi.org/10.13005/bpj/2176.

Full text

Abstract:

Introduction: Urolithiasis is quite a common disorder affecting around two million people in India every year. Minimally invasive therapies are effective treatment measures in most of the cases. However, a watchful waiting approach with pharmacotherapy promotes the expulsion of stones in a shorter time. We hereby review the efficacy and safety of silodosin, a selective α-1A adrenoceptor antagonist, in medical expulsive therapy for the management of urolithiasis based on the evidences in Indian population. Methods: Medical Subject Headings (MeSH) keywords which were used to systematically search electronic databases: PubMed/Medline, Cochrane Library and Google Scholar from their inception to February 2020 were “Silodosin”, “Ureteral calculi”, “Medical expulsive therapy”, “India”, “randomised controlled trials” and “prospective observational studies”. A total of 29 relevant studies could be found and were included in our analysis. Results: The primary outcomes considered were the stone expulsion rate (SER) and stone expulsion time (SET) along with pain episodes and safety outcomes like orthostatic hypotension and retrograde ejaculation. Eight studies with a total of 1064 patients were identified as evidences considering Indian population which compared silodosin with controls like tamsulosin or tadalafil. Conclusions: Silodosin is highly effective in Indian population for increasing stone expulsion for those with ureteral stones (distal ureteral stones with diameter ≥5 mm and ≤10 mm) with shorter expulsion times along with fewer episodes of pain. It is also effective in post-lithotripsy for accentuating clearance rate and curtailing time to passage of the stones.

APA, Harvard, Vancouver, ISO, and other styles

21

Karamık, Kaan, Mehmet Kısaarslan, Hakan Anıl, and Nihat Ateş. "Efficacy of tamsulosin versus silodosin as medical expulsive therapy on stone expulsion in patients with distal ureteral stone: A retrospective single center study." Yeni Üroloji Dergisi 18, no. 1 (February 27, 2023): 1–7. http://dx.doi.org/10.33719/yud.2023;18-1-1118339.

Full text

Abstract:

Objective: This study aimed to compare the efficacy of tamsulosin and silodosin as medical expulsive therapy in patients with symptomatic uncomplicated distal ureteric stones. Material and Methods: The data of adult patients who had distal ureteric stones in size between 4 and 10 mm and were treated with medical expulsive therapy between June 2019 and January 2022 were retrospectively documented. Patients were divided into two groups. Patients in Group 1 received silodosin 4 mg, and Group 2 received tamsulosin 0.4 mg. Therapy was given for a maximum of 3 weeks. Stone expulsion rate, time to stone expulsion, stone burden, and stone size were recorded. The efficacy of tamsulosin and silodosin as adjunctive medical therapy was determined. Results: A total of 152 patients were included in the study. Demographic profiles were comparable between the 2 groups. 116 (76.3%) patients were stone-free at the end of the follow-up. The stone expulsion rate was calculated in 47 patients (73.4%) in Group 1, and 69 patients (78.4%) in Group 2 (P = 0.477). The distance of the stone to the ureterovesical junction was significantly associated with successful stone expulsion in multivariate analysis (P=0.032). Conclusion: There was no significant superiority between tamsulosin and silodosin as medical expulsive therapy for distal ureteral stones. The distance of the stone to the ureterovesical junction was the only independent predictor of stone expulsion in multivariate analysis. Keywords: Medical expulsive therapy,

APA, Harvard, Vancouver, ISO, and other styles

22

Gill, Shivkaran, Rachhpal Singh, and Neeti Rajan Singh. "Effect of silodosin in post operative retention of urine." International Surgery Journal 7, no. 5 (April 23, 2020): 1378. http://dx.doi.org/10.18203/2349-2902.isj20201562.

Full text

Abstract:

Background: Post-operative urinary retention (POUR) is a common yet potentially serious morbidity with a reported incidence of 3 to 25%. This study aims to evaluate the effect of Silodosin, a super-selective alpha- 1a adrenergic blocking agent, as prophylaxis for post operative urinary retention in patients undergoing various surgical procedures.Methods: 100 patients were divided into two groups of 50 each. In group 1, patients were given prophylactic silodosin to evaluate its effect in post operative retention of urine and in group 2, patients were not given any medication.Results: In this study, POUR was diagnosed. POUR was higher in the older age group i.e. more in the age group of 41-60 yrs but in group 1, it was less as compared to group 2. POUR rate in general anaesthesia (GA) patients are less (11.1%) in group 1 as compared to (23.6%) in group 2. POUR rate in spinal anaesthesia (SA) patients are more (21.4%) in group 1 as compared (16.6%) in group 2. The total POUR rate in group 1 was lower (14%) as compared to (22%) in group 2.Conclusions: In our opinion patients operated under GA, irrespective of gender and type of surgery will benefit from prophylactic silodosin given in pre-operative period for the prevention of POUR and we highly recommend this. Patients who were operated under SA were not benefitted by giving prophylactic silodosin. Probably this is due to use of long acting spinal anesthetic agent in the form of bupivacaine in our patients.

APA, Harvard, Vancouver, ISO, and other styles

23

Strittmatter, Frank, and Petter Hedlund. "Silodosin: pharmacological and clinical features." Aging Health 7, no. 1 (February 2011): 45–57. http://dx.doi.org/10.2217/ahe.10.81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Çelik, Serdar, Firat Akdeniz, Muge Afsar Yildirim, Ozan Bozkurt, Merve Gursoy Bulut, Mehmet Levent Hacihasanoglu, and Omer Demir. "Tadalafil versus alpha blockers (alfuzosin, doxazosin, tamsulosin and silodosin) as medical expulsive therapy for < 10 mm distal and proximal ureteral stones." Archivio Italiano di Urologia e Andrologia 90, no. 2 (June 30, 2018): 117. http://dx.doi.org/10.4081/aiua.2018.2.117.

Full text

Abstract:

Objectives: To evaluate the effect of tadalafil compared with four alpha blockers (alfuzosin, doxazosin, tamsulosin and silodosin) as medical expulsive treatment for ureteral stones in male adults. Materials and methods: Male adults who were admitted to urology clinic with flank pain and diagnosed with non complicated < 10 mm ureteral stone on non-contrast computed tomography (NCCT) between June 2014-September 2015 were retrospectively evaluated. A total of 273 patients with ureteral stone were divided into five groups. Alfuzosin 10 mg/daily, doxazosin 8 mg/daily, tamsulosin 0.4 mg/daily, silodosin 8 mg/daily and tadalafil 5 mg/daily for 6 weeks were prescribed respectively. Stone localization, diameter, volume and Hounsfield units were noted as NCCT findings. The patients were divided into the two groups based on their stone localization as distal and mid-proximal stones. These two groups were evaluated separately. Expulsion rate were noted at the end of 6 weeks. NCCT and treatment findings were compared between five drug groups in distal and mid-proximal stones separately. Results: Age was higher in tadalafil group in distal stones (p = 0.032). Expulsion rate was found 78.1% for alfuzosin, 75.7% for doxazosin, 76.5% for tamsulosin, 88.6% for silodosin and 90% for tadalafil in distal (p = 0.44) and 21.7%, 30%, 30%, 30% and 54.5% in mid-proximal stones (p = 0.034) respectively.Conclusions: Expulsion rate was higher in silodosin and tadalafil for distal ureteral stones but the difference didn’t meet statistical significance. However the expulsion rate was significantly higher in tadalafil than in the other groups for mid-proximal ureteral stones. The result of this study showed that tadalafil may increases ureteric stone expulsion.

APA, Harvard, Vancouver, ISO, and other styles

25

Gnana, Bhushan Kumar, and Sanjeeva Rao Matlapudi. "A comparative clinical evaluation of outcome of medical and surgical management of symptoms due to benign prostatic hyperplasia." International Surgery Journal 7, no. 9 (August 27, 2020): 3032. http://dx.doi.org/10.18203/2349-2902.isj20203789.

Full text

Abstract:

Background: Benign hypertrophy of prostate is common disorder and benign neoplasm of man above 50 years of age. Around 30% patients with benign hypertrophy of prostate lower urinary tract symptoms (LUTS) but all symptoms may not be due to benign hypertrophy of prostate (BHP). Present study has been designed for comparative evaluation of the outcome of medical and surgical management of symptoms, due to benign prostatic hyperplasia by using IPSS (international prostate score) and quality of life score as tool.Methods: In present study patients with LUTS, clinically diagnosed by per rectal digital examination and transrectal ultrasonographically confirmed cases of enlargement of prostate are enrolled for this study. Patients enrolled were divided equally in three groups.Results: After six month the mean IPSS score in silodosin (Sd) group was 6.55±0.86 and in Sd+Dutasteride (Dt) group it was 5.09±1.12. After six months mean IPSS score in Sd+Dt group was 5.09±1.12 and in TURP group it was 2.44±0.59.Conclusions: Single drug treatment with silodosin is associated with slow and less improvement in IPSS score in comparison with silodosin and dutasteride. But the response to TURP was better and faster than medical management.

APA, Harvard, Vancouver, ISO, and other styles

26

Arafat, Mohammad Ali, Masud Rana, Md Shakil Akhter, and Tohid Md Saiful Hossain. "A Comparison of Safety and Efficacy between Silodosin Monotherapy Versus Silodosin with Tadalafil add on Therapy in Patients with Benign Prostatic Hyperplasia." Bangladesh Journal of Urology 24, no. 2 (September 2, 2022): 205–13. http://dx.doi.org/10.3329/bju.v24i2.59496.

Full text

Abstract:

Background: For relieving symptoms of LUTS due to BPH treatment modalities are watchful waiting, medical treatment and surgery. Among medical treatment, options are alpha 1 adrenoreceptor blockers, 5 alpha reductase inhibitors and recently introduced phospodiesterase 5 inhibitors or combination therapy. Objective: To compare the safety and efficacy of silodosin versus silodosin and tadalafil for treating patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: This prospective observational study was conducted in the Department of Urology, BSMMU, Dhaka from April 2020 to March 2021. A total of 66 patients with LUTS due to BPH were selected by purposive sampling on the basis of selection criteria from OPD of Urology, BSMMU. They were randomly divided into two groups: according to odd or even hospital number and label as A group (odd no) and B group (even no). Group-A were provided with silodosin 8.0 mg daily and group-B were provided with silodosin 8.0 mg and tadalafil 5.0 mg daily (B group). Two patients from each group were excluded due to adverse effect and one patients from each group was lost to follow-up. Final analysis was done on sixty patients (30 from each group). The patients were assessed by IPSS, Qmax and PVR. The results were expressed as frequency & percentage (categorical data) and mean ± SD (numerical data). Unpaired t-tests and paired t tests were performed as applicable using SPSS 22.0 and p <0.05 was considered as the level of significance. Results: Out of sixty six patients, sixty patients completed the study. Two patients from group A was suffering from hypotension and headache and two patients from group B was suffering from ejaculatory dysfunction and dizziness, one patient from each group was lost after 1st follow up, so they were excluded from study. Maximum study subjects were within 51 to 70 years of age in both groups. Mean age of the study subjects was 57.13 ± 9.36 years in Group-A and 59.33 ± 7.09 years in Group-B. Mean prostate volume of the study subjects was 37.93 ± 13.19 ml in Group-A and 35.50 ± 10.57 ml in Group-B. IPSS was reduced to 21.90±3.68 after 6 weeks and 18.90 ± 3.79 after 12 weeks from 25.10 ± 3.96 prior to treatment in Group-A. Similarly, in Group-B, IPSS was reduced from 19.67 ± 3.45 after 6 weeks and 16.37 ± 2.03 after 12 weeks from 23.03 ± 4.16 prior to treatment. PVR decreased to 58.00 ± 20.41 after 6 weeks and 42.10 ± 17.40 after 12 weeks from 74.15 ± 26.40 prior to treatment in Group-A. Similarly, PVR in Group-B reduced to 52.70 ± 12.51 after 6 weeks and 33.57 ± 8.97 after 12 weeks from 66.17 ± 15.50 before treatment. After 6 weeks, Qmax increased to 15.67 ± 2.11 and at 12 weeks17.73 ± 2.66 from 13.39 ± 1.83 before treatment in Group-A. Similarly, after 6 weeks, Qmax in Group- B increased to 16.74 ± 1.14 and at 12 weeks18.94±1.31 from 14.17±1.28 before treatment. Conclusion: Improvements in both silodosin (alpha blocker) group and silodosin in combination with tadalafil (PDE 5 inhibitor) group were found to be effective, safe and satisfactory in treating patients with symptomatic BPH. Even though combination group showed better efficacy than silodosin monotherapy group but as per improvement rate it was not statistically significant. Bangladesh J. Urol. 2021; 24(2): 205-213

APA, Harvard, Vancouver, ISO, and other styles

27

Hagiwara, Kazuhisa, Takuya Koie, Hiromichi Iwamura, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, and Chikara Ohyama. "Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study." BioMed Research International 2016 (2016): 1–5. http://dx.doi.org/10.1155/2016/4975851.

Full text

Abstract:

This study aimed to assess the efficacy of combination therapy with dutasteride and silodosin in patients with acute urinary retention (AUR) caused by benign prostatic hyperplasia (BPH). Eighty consecutive patients with a first episode of AUR were enrolled in this study. All patients received silodosin 8 mg and dutasteride 0.5 mg daily. Trial without catheter (TWOC) was attempted every 2 weeks until 12 weeks after the initiation of medication. The primary endpoint was the rate of catheter-free status at 12 weeks. Voided volume (VV), postvoid residual urine (PVR), uroflowmetry, International Prostatic Symptoms Score (IPSS), and quality of life due to urinary symptoms (IPSS-QOL) were also measured. All patients were followed up for more than 12 weeks and were included in this analysis. The success rate of TWOC at 12 weeks was 88.8%. VV and maximum urinary flow rate were significantly higher at 2, 4, 8, and 12 weeks compared with the time of AUR (P<0.001). IPSS and IPSS-QOL were significantly lower at 2, 4, 8, and 12 weeks compared with the time of AUR (P<0.001). In conclusion, a combination of dutasteride and silodosin therapy may be effective and safe for patients with AUR due to BPH.

APA, Harvard, Vancouver, ISO, and other styles

28

MUTO, Shin-ichi, Hiroko KASAHARA, Ryohei YOKOI, Morimichi HAYASHI, Shinji SOUMA, Kazuo KOBAYASHI, Toru TAMURA, Makoto MURAKAMI, Jinji KURODA, and Nobuo SHIBATA. "Toxicity Profile of Silodosin (KMD-3213)." YAKUGAKU ZASSHI 126, Special (March 1, 2006): 247–56. http://dx.doi.org/10.1248/yakushi.kj00004483560.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

MUTO, Shin-ichi, Hiroko KASAHARA, Ryohei YOKOI, Morimichi HAYASHI, Shinji SOUMA, Kazuo KOBAYASHI, Toru TAMURA, Makoto MURAKAMI, Junji KURODA, and Nobuo SHIBATA. "Toxicity Profile of Silodosin (KMD-3213)." YAKUGAKU ZASSHI 126, Special_Issue (2006): 247–56. http://dx.doi.org/10.1248/yakushi.126.247.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Chatterjee, Samrat, and Deepshikha Agrawal. "Silodosin-associated intraoperative floppy iris syndrome." Indian Journal of Ophthalmology 65, no. 6 (2017): 538. http://dx.doi.org/10.4103/ijo.ijo_704_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Er, Engin, Hüseyin Çelikkan, and Nevin Erk. "An ultra-sensitive 2D electrochemical sensor based on a PtNPs@graphene/Nafion nanocomposite for determination of α1-AR antagonist silodosin in human plasma." Analytical Methods 9, no. 25 (2017): 3782–89. http://dx.doi.org/10.1039/c7ay00992e.

Full text

Abstract:

An ultra-sensitive and selective 2D electrochemical sensor based on a PtNPs@GRP/NFN nanocomposite was developed for routine detection of α₁-AR antagonists such as silodosin in human plasma.

APA, Harvard, Vancouver, ISO, and other styles

32

Lobkarev, A. O., R. Kh Khafiz'yanova, and O. A. Lobkarev. "Comparative analysis of clinical effectiveness of α1-adrenoblockers doxazosin, tamsulosin and silodosin in males with chronic non-inflammatory prostatitis." Kazan medical journal 99, no. 6 (December 15, 2018): 880–86. http://dx.doi.org/10.17816/kmj2018-880.

Full text

Abstract:

Aim. Comparative study of clinical effectiveness of doxazosin, tamsulosin and silodosin as monotherapy for patients with chronic non-inflammatory prostatitis. Methods. Outpatient medical records (OMR) of patients with the diagnosis of chronic non-inflammatory prostatitis who were treated in “The clinic of ambulatory urology” (Kazan) in 2012-2017, were analyzed: all 173 OMR of patients receiving doxazosin 1 mg QD for 30 days as monotherapy; all 150 OMR of patients receiving doxazosin 2 mg per day BID for 30 days as monotherapy; all 54 OMR of patients receiving doxazosin 4 mg per day BID for 30 days as monotherapy; all 77 OMR of patients receiving tamsulosin 0.4 mg QD for 30 days as monotherapy; all 36 OMR of patients receiving silodosin 8 mg QD for 30 days as monotherapy. Based on these OMR the “Clinical index of chronic prostatitis” (CI CP) was analyzed before the start of pharmacotherapy and 30 days after the beginning. According to the clinical index, the discrete sample was ordered containing the values of CI from 0 points (no complaints) to 50 points (maximal score - the most marked symptoms). Results. Before the beginning of the treatment every sample of patients is homogeneous and after 30-day treatment they lose homogeneity and tend to divide into several homogeneous samples. Conclusion. Clinical effectiveness of doxazosin, tamsulosin and silodosin in men with CNP varies in wide range, is poorly predictable, poorly explainable and needs further studies according to the principles of modern evidence-based medicine.

APA, Harvard, Vancouver, ISO, and other styles

33

Rangaiah, Rohit Garagadahalli, and Vilvapathy Senguttuvan Karthikeyan. "Role of alpha blockers and 7-days catheterization in enhancing the success of trial void in acute urinary retention due to benign prostatic hyperplasia: a double-blind randomized control trial." International Surgery Journal 5, no. 10 (September 25, 2018): 3256. http://dx.doi.org/10.18203/2349-2902.isj20184072.

Full text

Abstract:

Background: Acute urinary retention (AUR) in patients with benign prostatic hyperplasia (BPH) is common. This study evaluated the efficacy of three alpha-blockers with urethral catheterization for 7 days in trial without catheter (TWOC).Methods: This was a prospective, randomized, double-blind, active-control study conducted between November 2013 and May 2016. Patients aged more than 50 years, presenting with first-time painful AUR due to BPH were enrolled in this study. Eligible patients were randomized (1:1:1) to one of the three treatment groups to receive tamsulosin 0.4 mg, alfuzosin 10 mg or silodosin 8 mg for one week. The primary outcome measure was successful TWOC at 7 days.Results: A total of 118 patients were included in the study (tamsulosin, n=40; alfuzosin, n=38; and silodosin, n=40). The baseline parameters were comparable between the three groups. A total of 84 (71.2%) patients had successful TWOC at the end of 7 days (tamsulosin, n=30 (75%); alfuzosin, n=32 (84%); and silodosin, n=22 (55%)) and was significantly (p=0.015) different between three groups. Higher age, larger volume at retention and higher prostate volume were significantly (p<0.05) associated with the failure of TWOC.Conclusions: Results from this study demonstrate that there is a definite role of 7-day catheterization with alpha blockers in improving the rates of success of TWOC in men presenting with AUR due to BPH. The success of TWOC is multifactorial.

APA, Harvard, Vancouver, ISO, and other styles

34

Yoshida, Takashi, Hidefumi Kinoshita, Seiji Shimada, Makoto Taguchi, and Tadashi Matsuda. "Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia." Urology 106 (August 2017): 153–59. http://dx.doi.org/10.1016/j.urology.2017.04.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Benedict, Aquinas, Vinothkumar Rajenthiran, and Abhinaya Eswaramurthy. "Effects of silodosin, darifenacin, and combination therapy for the treatment of ureteral stent related discomforts." International Surgery Journal 8, no. 10 (September 28, 2021): 3031. http://dx.doi.org/10.18203/2349-2902.isj20213989.

Full text

Abstract:

Background: To evaluate the effect of silodosin, darifenacin and combination therapy of two agents in improving the lower urinary tract symptoms of patients with indwelling double-J ureteral stents.Methods: A total of 150 patients underwent placement of a double-J ureteral stent after retrograde ureteroscopy for urinary stone disease. All patients received polyurethane double-J ureteral stents (4 Fr and length 26 cm), which were removed at a mean of around 14 days postoperatively. A total of 40 patients were given no medication (group 1), 39 patients were given silodosin 4 mg once daily (group 2), 40 patients were given darifenacin 7.5 mg once daily (group 3), and 31 patients were given a combination of two agents postoperatively (group 4). International prostate symptom score (IPSS) and visual analogue pain scale (VAPS) questionnaires were completed by each patient at 1st day postoperatively and on the day of stent removal.Results: In the total group of patients, the mean age was 50.24±12.90 years. There was a significant difference in the IPSS total score between group 1 and groups 3 and 4. Group 4 also differed significantly from group 1 in the irritative subscore. The obstructive subscore differed between groups 2 and 4 and group 1. There was a statistically significant difference between group 1 and group 4 in the quality of life (QoL) score.Conclusions: Combination therapy with silodosin and darifenacin improved both irritative and obstructive symptoms more than in the other groups. Combination therapy should be strongly considered for patients who complain of stent-related symptoms.

APA, Harvard, Vancouver, ISO, and other styles

36

Kahkashan, Iram, Shabnam Chawdhary, Vishal R. Tandon, and Rahul Gupta. "To compare the efficacy and safety of silodosin and dutasteride combination with alfuzosin and dutasteride combination in patients of benign prostatic hyperplasia: a randomized, open label study." International Journal of Basic & Clinical Pharmacology 8, no. 4 (March 23, 2019): 635. http://dx.doi.org/10.18203/2319-2003.ijbcp20191095.

Full text

Abstract:

Background: BPH is a major cause of bothersome lower urinary tract symptoms (LUTS) and affects quality of life (QoL) which deteriorates if not taken care with the passage of time. The aim and objective of the study was to compare the efficacy and safety of combination of silodosin and dutasteride with the combination of alfuzosin and dutasteride in patients of BPH.Methods: A randomized, open label, intention to treat study was carried out on newly diagnosed patients of BPH. Patients were randomly divided into two groups and followed up to 12 weeks. Group 1 of patients received a combination of silodosin 8 mg and dutasteride 0.5 mg (SD) (n=20) while the patients of group 2 received combination of alfuzosin 10 mg and dutasteride 0.5 mg (AD) (n=20). Primary endpoint was measured by changes in the mean baseline International prostate symptom score (I-PSS) and uroflowmetry and secondary outcome with changes observed on ultrasonography.Results: IPSS and IPSS-QOL significantly improved in both the treatment groups (p <0.001) along with mean maximum flow rate (Qmax) and mean average flow rate (Qavg). Prostate volume and residual urine volume showed a significant improvement in both the treatment groups at 12 weeks. However, the intergroup differences in IPSS, uroflowmetry and USG parameters were not significant. Both treatments were well tolerated.Conclusions: The current study established that both the drug combinations i.e. silodosin and dutasteride (SD) and alfuzosin and dutasteride (AD) largely have a comparable effect on both the dynamic and static components of BPH. Further, both drug combinations appear to have a comparable safety profile.

APA, Harvard, Vancouver, ISO, and other styles

37

Yoshizumi, Masaru, Kazumasa Matsumoto-Miyai, Akihiko Yonezawa, and Masahito Kawatani. "Role of supraspinal and spinal α1-adrenergic receptor subtypes in micturition reflex in conscious rats." American Journal of Physiology-Renal Physiology 299, no. 4 (October 2010): F785—F791. http://dx.doi.org/10.1152/ajprenal.00553.2009.

Full text

Abstract:

α1-Adrenergic receptor subtypes are widely distributed in the central nervous system and are involved in autonomic functions such as micturition. We investigated the presence and the role of supraspinal and/or spinal α1-adrenergic receptors in modulating the micturition reflex in conscious female Wistar rats. The expression of α1-adrenergic receptor subtypes in rat brain and lumbosacral spinal cord was studied using RT-PCR. Continuous-infusion cystometrograms were obtained in conscious rats, and α1-adrenergic receptor antagonists were administered via intracerebroventricular or intrathecal routes. The mRNA expression of α1A-, α1B-, and α1D-adrenergic receptors was detected in rat brain (midbrain and pons) and lumbosacral spinal cord (dorsal and ventral parts of spinal cord). In addition, intracerebroventricular injection of the α1-adrenergic receptor antagonist tamsulosin (1–10 μg), the selective α1A-adrenergic receptor antagonist silodosin (1–10 μg), and the selective α1D-adrenergic receptor antagonist BMY 7378 (1–10 μg) significantly prolonged the intercontraction interval (ICI) but did not alter maximum voiding pressure (MVP). Although intrathecal injection of BMY 7378 (0.0001–10 μg) did not affect ICI, tamsulosin and silodosin prolonged ICI in a dose-dependent manner. MVP was significantly reduced by intrathecal injection of tamsulosin (10 μg) but not by silodosin or BMY 7378 (0.0001–10 μg). Supraspinal α1A- and α1D-adrenergic receptors are apparently important for the regulation of reflex-bladder activity in conscious rats. Noradrenergic projection from the brain stem to the lumbosacral spinal cord may promote the afferent limb rather than the efferent limb of the micturition reflex pathway via α1A-adrenergic receptors.

APA, Harvard, Vancouver, ISO, and other styles

38

Brohi, Illahi Bux, Muhammad Shahid Bhatti, Roshan Ali Siyal, Farhan Ali, Zulfiqar Kaimkhani, and Hamid Raza Laghari. "EFFICACY OF ALPHA-ADRENERGIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF DISTAL URETERIC STONES: A PAEDIATRIC STUDY." Journal of Ayub Medical College Abbottabad 34, no. 4 (September 27, 2022): 811–15. http://dx.doi.org/10.55519/jamc-04-10379.

Full text

Abstract:

Background: European association of urology (EAU) recommended α- blockers for managing distal ureteric stones in the paediatric population. This paper will help to understand the efficacy of Silodosin as a medical expulsive agent for distal ureteric stones in children, along with the required time duration of stone expulsion. Methods: Forty participants were enrolled and evaluated for complaints, pain severity, associated symptoms, and ultrasound was done to confirm the position and size of the distal stone. Follow-ups were scheduled after every 7 days (1 week) for redo ultrasound and assessment of the stone position. Data was entered and analyzed in the SPSS version 23. To evaluate the significance of data chi-square test was performed, p-value <0.005 was considered significant. Results: The minimum and maximum age limits recorded are 3 years and 18 years respectively with a mean age of 9.5±4.5 years and mean stone size was measured as 0.6±0.1 cm. Distribution of stone size indicated the minimum size of 0.4 cm and maximum of 1.0 cm stone in study subjects. Maximum stone expulsion was reported within 14 days or an initial 2 follow-up scans. Conclusion: The efficacy of Silodosin and medical expulsive therapy evaluated the effect on pain management as pain episodes declined with Silodosin treatment and spontaneous passage of stones were increased within the first 14 days of treatment. This study will be a beneficial contribution in literature especially in a developing country population where paediatric urolithiasis is on expansion and ongoing

APA, Harvard, Vancouver, ISO, and other styles

39

Cheeseman, M. "Silodosin to tackle urinary symptoms of BPH." Inpharma Weekly &NA;, no. 1659 (October 2008): 9–10. http://dx.doi.org/10.2165/00128413-200816590-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Silodosin approved for BPH in the US." Inpharma Weekly &NA;, no. 1660 (October 2008): 18. http://dx.doi.org/10.2165/00128413-200816600-00065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Silodosin shows potential in BPH with LUTS." Inpharma Weekly &NA;, no. 1492 (June 2005): 9. http://dx.doi.org/10.2165/00128413-200514920-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Ipekci, Tumay, Yigit Akin, Burak Hoscan, and Ahmet Tunckiran. "Intraoperative floppy iris syndrome associated with silodosin." Acta Ophthalmologica 93, no. 4 (August 31, 2014): e306-e306. http://dx.doi.org/10.1111/aos.12549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Yamanishi, Tomonori. "Management of benign prostatic hyperplasia with silodosin." Research and Reports in Urology Volume 1 (August 2009): 1–7. http://dx.doi.org/10.2147/rru.s5004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

MATSUBARA, Yasuhito, Toru KANAZAWA, Yasunari KOJIMA, Yoshikazu ABE, Kaoru KOBAYASHI, Hiroki KANBE, Hiroshi HARADA, et al. "Pharmacokinetics and Disposition of Silodosin (KMD-3213)." YAKUGAKU ZASSHI 126, Special (March 1, 2006): 237–45. http://dx.doi.org/10.1248/yakushi.kj00004483559.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

SHIMIZU, Tomoji, Itaru MIYASHITA, Yasuhito MATSUBARA, Mitsugu IKEDA, and Masayuki YAMAGUCHI. "Pharmacokinetic Profile of Silodosin in Clinical Practice." YAKUGAKU ZASSHI 126, Special (March 1, 2006): 257–63. http://dx.doi.org/10.1248/yakushi.kj00004483561.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

MATSUBARA, Yasuhito, Toru KANAZAWA, Yasunari KOJIMA, Yoshikazu ABE, Kaoru KOBAYASHI, Hiroki KANBE, Hiroshi HARADA, et al. "Pharmacokinetics and Disposition of Silodosin (KMD-3213)." YAKUGAKU ZASSHI 126, Special_Issue (2006): 237–45. http://dx.doi.org/10.1248/yakushi.126.237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

SHIMIZU, Tomoji, Itaru MIYASHITA, Yasuhito MATSUBARA, Mitsugu IKEDA, and Masayuki YAMAGUCHI. "Pharmacokinetic Profile of Silodosin in Clinical Practice." YAKUGAKU ZASSHI 126, Special_Issue (2006): 257–63. http://dx.doi.org/10.1248/yakushi.126.257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Sato, Y., T. Otani, T. Amano, and T. Araki. "1002 Effect of silodosin on premature ejaculation." European Urology Supplements 15, no. 3 (March 2016): e1002. http://dx.doi.org/10.1016/s1569-9056(16)61003-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Inoue, Akiha, Yu Sawada, Shun Ohmori, Daisuke Omoto, Sanehito Haruyama, Manabu Yoshioka, Daisuke Nisio, and Motonobu Nakamura. "Maculopapular type drug eruption caused by silodosin." Allergology International 65, no. 2 (April 2016): 219–20. http://dx.doi.org/10.1016/j.alit.2015.11.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rahman, Md Jawaid, M. Shazib Faridi, Naloh Mibang, and Rajendra Sinam Singh. "Comparing tamsulosin, silodosin versus silodosin plus tadalafil as medical expulsive therapy for lower ureteric stones: A randomised trial." Arab Journal of Urology 16, no. 2 (June 2018): 245–49. http://dx.doi.org/10.1016/j.aju.2017.11.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Silodosin'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles